Drug Database
AP

apomorphine (apomorphine, Chiesi / Apofin / Apofin Stylo)

✓ Approved

Chiesi Farmaceutici S.p.A. · DRD2 · 小分子

什么是 apomorphine?

apomorphine 是一种小分子,由Chiesi Farmaceutici S.p.A.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名apomorphine, Chiesi, Apofin, Apofin Stylo
公司Chiesi Farmaceutici S.p.A.
药物类别小分子
分子靶点DRD2
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

apomorphine 作用于 1 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

apomorphine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersParkinson's disease✓ Approved

相关研究文献

PubMedBrain communications2026-11-15

Pharmacological treatments in disorders of consciousness.

Saleh Christian C, Seyfzadeh Fatemeh F, Szymkowicz Emilie E, Alnagger Naji N et al.

Disorders of consciousness (DoC) are among the most severe and devastating neurological conditions. The poorly understood underlying pathophysiology of DoC renders the search for adequate treatment options particularly difficult. The aim of this narrative review is to provide an overview of currently available pharmacological treatments, report the limitations of current research and discuss future directions, notably potential new treatments, advances in modelling approaches, potential mechanisms of action and the development of a standardized registry. We review pharmacological treatments that promote the recovery of consciousness in patients with DoC acting on dopaminergic (amantadine, levodopa, apomorphine, methylphenidate, bromocriptine, modafinil and selegiline) and GABAergic (zolpidem, baclofen and midazolam) pathways, as well as other pharmacological treatments (tricyclic antidepressants, anticonvulsants and simvastatin) and the combination of different treatments. The literature includes a limited number of randomized controlled trials (RCTs) alongside a large body of retrospective studies and case reports, which are classified as class IV evidence. Reported improvements in arousal or responsiveness are inconsistent, reflecting marked heterogeneity in patient populations, dosing regimens and outcome measures. Risk-of-bias assessment indicated that 12 of 22 RCTs (∼55%) exhibit some concerns or a high risk of bias. Multiple correspondence analysis yielded a descriptive mapping of RCT characteristics, demonstrating how pharmacological trials in DoC are grouped. Although mechanistic hypotheses converge on dopaminergic, GABAergic and thalamocortical modulation, the current literature on pharmacological treatments in DoC remains poorly reproducible. Given the significant methodological variability (e.g. study design, patient characteristics and outcome measures) across studies, current evidence does not allow firm conclusions regarding the most effective consciousness-enhancing pharmacological treatments in DoC. To make informed decisions in terms of pharmacological treatments and move towards personalized care for patients with DoC, rigorously designed multicentre controlled trials with harmonized outcome measures conducted with mechanistic and computational approaches are required. This can be achieved through an international registry to standardize data collection and improve reproducibility and replicability.

PMID 43032840
阅读全文 →
PubMedClinical neuropharmacology2026-11-12

Subcutaneous Apomorphine for OFF-related Pain in Parkinson Disease: A Randomized, Double-blind, Placebo-controlled Cross-over Pilot Trial.

Alizadeh Parisa P, Abusrair Ali A, Amorelli Gabriel G, Naser Kinza K et al.

OFF-related pain is a disabling and underrecognized nonmotor symptom of Parkinson disease. Oral dopaminergic therapy may provide inconsistent relief due to erratic gastrointestinal absorption and fluctuating levodopa levels. Subcutaneous apomorphine, a rapid-acting dopamine agonist, may represent a rational rescue strategy. We conducted a single-center, randomized, double-blind, placebo-controlled, 2-period cross-over pilot trial in Parkinson disease patients with motor fluctuations and reproducible OFF-related pain. Participants received subcutaneous apomorphine (2 mg followed by 3 mg) and placebo on separate visits 1 week apart during defined OFF states established by withholding antiparkinsonian medications overnight for at least 12 hours. The primary outcome was the change in pain severity measured by visual analogue scale (VAS) 30 minutes after the 3 mg dose (90 min from baseline). Secondary outcomes included Movement Disorder Society-Unified Parkinson Disease Rating Scale Part III (MDS-UPDRS Part III) scores, Clinical Global Impression (CGI), and adverse events. Eleven participants were randomized; 10 completed both treatment periods. At the primary endpoint (n=7 paired), apomorphine produced greater pain reduction than placebo (Hodges-Lehmann median difference -3.85; 95% CI: -6.90 to -1.85; P=0.016; dz=1.57). Motor improvement paralleled analgesic response and correlated with pain reduction (ρ=0.68; P=0.030). Adverse events were mild and comparable between treatments. Subcutaneous apomorphine was associated with clinically meaningful improvements in OFF-related pain and motor symptoms in this pilot cross-over trial. These findings support further evaluation of dopaminergic rescue therapy as a potential treatment strategy in larger studies.

PMID 43018477
阅读全文 →
PubMedBioanalysis2026-11-09

Quantification of D55, an apomorphine derivative, in mouse plasma by LC-MS/MS: method development, validation, and improved pharmacokinetics compared with apomorphine.

Nagai Kohei K, Kimura Natsuka N, Ishima Tamaki T, Osaka Hitoshi H et al.

Apomorphine exhibits anti-cell death activity in mitochondrial disease models, but its short elimination half-life and dopaminergic activity limit its therapeutic application. D55 is a modified apomorphine derivative with enhanced anti-cell death activity and no dopaminergic effects. We established and validated a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of D55 and apomorphine in mouse plasma and characterized their pharmacokinetic profiles. Validation assessed selectivity, linearity, precision and accuracy, injection carryover, extraction recovery, matrix effects, dilution integrity, and stability. Male C57BL/6J mice (n = 5 per group) received a single subcutaneous dose of either compound (0.5 mg/kg), and plasma concentration-time data were analyzed by noncompartmental analysis. The assay required 10 μL of plasma. For D55, intra- and inter-day precision were ≤10.3%, and accuracy ranged from 86.9% to 108.6%. For apomorphine, precision was ≤6.8%, and accuracy ranged from 99.6% to 104.0%. D55 exhibited a half-life 3.13-fold longer than that of apomorphine (78.4 vs. 24.9 min) and higher systemic exposure (AUC0-∞), with geometric mean ratios of 2.60 on a mass-concentration basis (ng·min/mL) and 2.36 on a molar-concentration basis (nM·min). These findings support further development of D55 as a therapeutic candidate for mitochondrial diseases.

PMID 43000885
阅读全文 →
PubMedJournal of neurology2026-11-06

Discontinuation and optimization of device-aided therapies in Parkinson's disease: a prospective comparative real-world study.

Santos García Diego D, Solleiro Vidal Ángela Á, Blázquez Estrada Marta M, Mir Pablo P et al.

Comparative real-world evidence on device-aided therapy (DAT) persistence in Parkinson's disease (PD) is limited. We assessed discontinuation, reasons, optimization time, and associated factors. We analyzed the prospective multicenter DATs-PD GETM Spanish Registry (January 2024-May 2026), including deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), foslevodopa/foscarbidopa (fLD/fCD), levodopa-carbidopa intestinal gel (LCIG), and levodopa-entacapone-carbidopa intestinal gel (LECIG). Persistence and associated factors were examined using Kaplan-Meier and Cox regression analyses. Among 565 patients receiving 591 DATs, 170 (28.8%) treatments were discontinued: DBS 4.1% (4/97), CSAI 34.1% (45/132), fLD/fCD 34.7% (101/291), LCIG 28.6% (4/14), and LECIG 28.1% (16/57). Among infusion therapies, discontinuation was 33.6%, without significant differences in rates (p = 0.774) or Kaplan-Meier persistence (p = 0.701). Main reasons were adverse events (38.2%) and patient decision (25.3%). Mean optimization time was 61.6 ± 97.2 days (LECIG 19.6 ± 33.1; DBS 115.2 ± 118.3). Discontinuation was associated with institutional caregiving (HR 5.162, 95% CI 1.441-18.490), higher ON-state Hoehn and Yahr stage (HR 1.814, 95% CI 1.110-2.964), and longer daily OFF time (HR 1.093, 95% CI 1.002-1.193). Approximately one-third of infusion DATs were discontinued, with no significant persistence differences. Disease severity, OFF time, and caregiving environment were associated with discontinuation. Observational differences in selection and exposure preclude direct comparative-effectiveness conclusions.

PMID 42993214
阅读全文 →
PubMedJournal of neural transmission (Vienna, Austria : 1996)2026-10-31

Subcutaneous apomorphine and the nonmotor features of Parkinson's disease.

Auffret Manon M, Vérin Marc M, van Laar Teus T, Lees Andrew J AJ

Parkinson's disease (PD) is a heterogeneous, progressive neurodegenerative disorder in which nonmotor manifestations (autonomic, sleep-related, neuropsychiatric, and sensory) constitute integral components of the disease continuum, exerting a disproportionate influence on quality of life, long-term disability, and caregiver burden. These features comprise both persistent components intrinsic to neurodegeneration and state-dependent fluctuations mechanistically linked to the oscillating dopaminergic tone imposed by pulsatile oral therapy. Apomorphine occupies a singular pharmacological position among the PD armamentarium, distinguished by a receptor binding profile, physicochemical properties, and pharmacokinetics that set it apart from other dopamine agonists and from levodopa-based therapies. Nearly four decades of clinical experience have established its efficacy in attenuating motor fluctuations and dyskinesias via continuous subcutaneous infusion (CSAI). Its effects on the nonmotor dimension of PD remain however incompletely characterized, reflecting both limited research investment and methodological constraints inherent to nonmotor outcome assessment and to apomorphine therapy itself. This narrative review and expert opinion examines the pharmacological basis for apomorphine's putative nonmotor efficacy, clinical evidence across individual nonmotor domains and iatrogenic considerations before reassessing apomorphine's therapeutic positioning within the device-aided therapy landscape. Nonmotor features should be regarded as primary determinants of treatment decision-making rather than secondary endpoints. The emerging concept of "fluctuation-dominant" PD provides a framework in which nonmotor fluctuation burden alone may constitute sufficient indication for CSAI, with direct implications for patient selection, timing of initiation, and redefinition of therapeutic goals beyond motor control.

PMID 42965636
阅读全文 →
PubMedJournal of reproductive immunology2026-10-28

Metformin (DMBG) ameliorates diabetic erectile dysfunction via the AMPK/mTOR pathway in association with endothelial autophagy reactivation.

Chen Jiaxing J, Hu Lingyun L, Ding Yaqi Y, Zhou Wangguan W et al.

Diabetes mellitus erectile dysfunction (DMED) is a prevalent complication with limited treatment efficacy. Metformin (dimethylbiguanide, DMBG) shows therapeutic potential, but its underlying mechanisms remain unclear. This study investigated whether DMBG alleviates DMED in association with restored endothelial autophagy. A DMED rat model was induced by streptozotocin and validated by apomorphine screening. Rats were treated with DMBG or Sildenafil (positive control) for 30 days. Erectile function was assessed by intracavernosal pressure (ICP) and mean arterial pressure (MAP). Penile tissues were analyzed histologically and for autophagy markers. To decipher the cellular mechanism, primary cavernosal endothelial cells (PCECs) were isolated from each treatment group and subjected to functional assays including viability, angiogenesis, migration, and apoptosis. The role of the AMPK/mTOR pathway was interrogated through western blot and by using the AMPK inhibitor BAY-3827 in a rescue experiment. DMBG significantly restored erectile function and cavernosal endothelial integrity, comparable to Sildenafil. It downregulated elevated serum VEGF-A and upregulated impaired penile autophagy markers (LC3-II, BECLIN1, ATG5). PCECs from DMBG-treated rats exhibited rescued viability, angiogenesis, migration, and reduced apoptosis, alongside reactivated autophagy. Mechanistically, DMBG activated AMPK and inhibited mTOR phosphorylation in PCECs, increasing eNOS. These protective effects were substantially attenuated by AMPK inhibition. DMBG ameliorates DMED in association with improved endothelial function and reactivated autophagy. These beneficial effects are associated with activation of the AMPK/mTOR signaling pathway, highlighting a novel mechanistic basis for the use of DMBG in DMED management.

PMID 42950738
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多apomorphine